159 related articles for article (PubMed ID: 33678142)
1. Crosstalk of low density lipoprotein and liposome as a paradigm for targeting of 5-fluorouracil into hepatic cells: cytotoxicity and liver deposition.
Alanazi SA; Harisa GI; Badran MM; Alanazi FK; Elzayat E; Alomrani AH; Al Meanazel OT; Al Meanazel AT
Bioengineered; 2021 Dec; 12(1):914-926. PubMed ID: 33678142
[TBL] [Abstract][Full Text] [Related]
2. Cholesterol-Conjugate as a New Strategy to Improve the Cytotoxic Effect of 5-Fluorouracil on Liver Cancer: Impact of Liposomal Composition.
Alanazi SA; Harisa GI; Badran MM; Haq N; Radwan AA; Kumar A; Shakeel F; Alanazi FK
Curr Drug Deliv; 2020; 17(10):898-910. PubMed ID: 32072911
[TBL] [Abstract][Full Text] [Related]
3. Nano-erythrocyte membrane-chaperoned 5-fluorouracil liposomes as biomimetic delivery platforms to target hepatocellular carcinoma cell lines.
AlQahtani SA; Harisa GI; Badran MM; AlGhamdi KM; Kumar A; Salem-Bekhit MM; Ahmad SF; Alanazi FK
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):989-996. PubMed ID: 30873877
[TBL] [Abstract][Full Text] [Related]
4. Design of cholesterol arabinogalactan anchored liposomes for asialoglycoprotein receptor mediated targeting to hepatocellular carcinoma: In silico modeling, in vitro and in vivo evaluation.
Pathak P; Dhawan V; Magarkar A; Danne R; Govindarajan S; Ghosh S; Steiniger F; Chaudhari P; Gopal V; Bunker A; Róg T; Fahr A; Nagarsenker M
Int J Pharm; 2016 Jul; 509(1-2):149-158. PubMed ID: 27231122
[TBL] [Abstract][Full Text] [Related]
5. Design and development of folate appended liposomes for enhanced delivery of 5-FU to tumor cells.
Gupta Y; Jain A; Jain P; Jain SK
J Drug Target; 2007 Apr; 15(3):231-40. PubMed ID: 17454361
[TBL] [Abstract][Full Text] [Related]
6. Mannose Conjugated Starch Nanoparticles for Preferential Targeting of Liver Cancer.
Jain AK; Sahu H; Mishra K; Thareja S
Curr Drug Deliv; 2021; 18(3):369-380. PubMed ID: 32885751
[TBL] [Abstract][Full Text] [Related]
7. Comparative study of transfersomes, liposomes, and niosomes for topical delivery of 5-fluorouracil to skin cancer cells: preparation, characterization, in-vitro release, and cytotoxicity analysis.
Alvi IA; Madan J; Kaushik D; Sardana S; Pandey RS; Ali A
Anticancer Drugs; 2011 Sep; 22(8):774-82. PubMed ID: 21799471
[TBL] [Abstract][Full Text] [Related]
8. Targeted Nanoparticles for Co-delivery of 5-FU and Nitroxoline, a Cathepsin B Inhibitor, in HepG2 Cells of Hepatocellular Carcinoma.
Varshosaz J; Fard MM; Mirian M; Hassanzadeh F
Anticancer Agents Med Chem; 2020; 20(3):346-358. PubMed ID: 31566137
[TBL] [Abstract][Full Text] [Related]
9. Activated p53 with Histone Deacetylase Inhibitor Enhances L-Fucose-Mediated Drug Delivery through Induction of Fucosyltransferase 8 Expression in Hepatocellular Carcinoma Cells.
Okagawa Y; Takada K; Arihara Y; Kikuchi S; Osuga T; Nakamura H; Kamihara Y; Hayasaka N; Usami M; Murase K; Miyanishi K; Kobune M; Kato J
PLoS One; 2016; 11(12):e0168355. PubMed ID: 27977808
[TBL] [Abstract][Full Text] [Related]
10. Liposomes for targeting hepatocellular carcinoma: use of conjugated arabinogalactan as targeting ligand.
Shah SM; Goel PN; Jain AS; Pathak PO; Padhye SG; Govindarajan S; Ghosh SS; Chaudhari PR; Gude RP; Gopal V; Nagarsenker MS
Int J Pharm; 2014 Dec; 477(1-2):128-39. PubMed ID: 25311181
[TBL] [Abstract][Full Text] [Related]
11. A novel lactoferrin-modified stealth liposome for hepatoma-delivery of triiodothyronine.
Pireddu R; Pibiri M; Valenti D; Sinico C; Fadda AM; Simbula G; Lai F
Int J Pharm; 2018 Feb; 537(1-2):257-267. PubMed ID: 29294323
[TBL] [Abstract][Full Text] [Related]
12. Functionalized PAMAM-based Nanoformulation for Targeted Delivery of 5-Fluorouracil in Hepatocellular Carcinoma.
Chen S; Ouyang H; He D; Liu D; Wang X; Chen H; Pan W; Li Q; Xie W; Yu C
Curr Pharm Des; 2022; 28(25):2113-2125. PubMed ID: 35524673
[TBL] [Abstract][Full Text] [Related]
13. Physical PEGylation Enhances The Cytotoxicity Of 5-Fluorouracil-Loaded PLGA And PCL Nanoparticles.
Ashour AE; Badran M; Kumar A; Hussain T; Alsarra IA; Yassin AEB
Int J Nanomedicine; 2019; 14():9259-9273. PubMed ID: 31819428
[TBL] [Abstract][Full Text] [Related]
14. Hyaluronic acid-decorated liposomal nanoparticles for targeted delivery of 5-fluorouracil into HT-29 colorectal cancer cells.
Mansoori B; Mohammadi A; Abedi-Gaballu F; Abbaspour S; Ghasabi M; Yekta R; Shirjang S; Dehghan G; Hamblin MR; Baradaran B
J Cell Physiol; 2020 Oct; 235(10):6817-6830. PubMed ID: 31989649
[TBL] [Abstract][Full Text] [Related]
15. Preclinical studies of N₃-O-toluyl-fluorouracil-loaded lipid-based nanosuspensions in H₂₂-bearing mice.
Zhang J; Li M; Liu Z; Wang L; Liu Y; Zhang N
Int J Nanomedicine; 2014; 9():2741-51. PubMed ID: 24920908
[TBL] [Abstract][Full Text] [Related]
16. Galactosylated nanostructured lipid carriers for delivery of 5-FU to hepatocellular carcinoma.
Varshosaz J; Hassanzadeh F; Sadeghi H; Khadem M
J Liposome Res; 2012 Sep; 22(3):224-36. PubMed ID: 22385296
[TBL] [Abstract][Full Text] [Related]
17. Solid lipid-based nanoparticulate system for sustained release and enhanced in-vitro cytotoxic effect of 5-fluorouracil on skin Melanoma and squamous cell carcinoma.
Ali A; Madni A; Shah H; Jamshaid T; Jan N; Khan S; Khan MM; Mahmood MA
PLoS One; 2023; 18(2):e0281004. PubMed ID: 36854019
[TBL] [Abstract][Full Text] [Related]
18. Targeting liver cancer via ASGP receptor using 5-FU-loaded surface-modified PLGA nanoparticles.
Dangi R; Hurkat P; Jain A; Shilpi S; Jain A; Gulbake A; Jain SK
J Microencapsul; 2014; 31(5):479-87. PubMed ID: 24697169
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines.
Rangwala F; Williams KP; Smith GR; Thomas Z; Allensworth JL; Lyerly HK; Diehl AM; Morse MA; Devi GR
BMC Cancer; 2012 Sep; 12():402. PubMed ID: 22963400
[TBL] [Abstract][Full Text] [Related]
20. Folic acid-modified liposomal drug delivery strategy for tumor targeting of 5-fluorouracil.
Moghimipour E; Rezaei M; Ramezani Z; Kouchak M; Amini M; Angali KA; Dorkoosh FA; Handali S
Eur J Pharm Sci; 2018 Mar; 114():166-174. PubMed ID: 29247686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
